Literature DB >> 30673912

Meeting report: Metastasis Research Society (MRS) 17th Biennial conference and associated Young Investigator Satellite Meeting (YISM) on cancer metastasis.

Thomas Beadnell1, Lucia Borriello2,3, Jessica Christenson4, Jaime Fornetti5, Ian Guldner6, Ann Hanna7, Lenka Kyjacova8, Kristina Marinak-Whately9, Poliana Cristina de Melo Martins10, Mirja Rotinen11, Veronika Te Boekhorst12,13, Thomas R Cox14,15.   

Abstract

The Metastasis Research Society (MRS) 17th Biennial conference on metastasis was held on the 1st to the 5th of August 2018 at Princeton University, NJ, USA. The meeting was held around themes addressing notable aspects of the understanding and treatment of metastasis and metastatic disease covering basic, translational, and clinical research. Importantly, the meeting was largely supported by our patient advocate partners including Susan G. Komen for the Cure, Theresa's Research Foundation and METAvivor. There were a total of 85 presentations from invited and selected speakers spread across the main congress and presentations from the preceding Young Investigator Satellite Meeting. Presentations are summarized in this report by session topic.

Entities:  

Keywords:  Cancer metastasis research; Meeting report; Patient advocates

Mesh:

Year:  2019        PMID: 30673912     DOI: 10.1007/s10585-018-09953-y

Source DB:  PubMed          Journal:  Clin Exp Metastasis        ISSN: 0262-0898            Impact factor:   5.150


  63 in total

Review 1.  Stromagenesis: the changing face of fibroblastic microenvironments during tumor progression.

Authors:  Dorothy A Beacham; Edna Cukierman
Journal:  Semin Cancer Biol       Date:  2005-10       Impact factor: 15.707

2.  GITR pathway activation abrogates tumor immune suppression through loss of regulatory T cell lineage stability.

Authors:  David A Schaer; Sadna Budhu; Cailian Liu; Campbell Bryson; Nicole Malandro; Adam Cohen; Hong Zhong; Xia Yang; Alan N Houghton; Taha Merghoub; Jedd D Wolchok
Journal:  Cancer Immunol Res       Date:  2013-11       Impact factor: 11.151

Review 3.  The extracellular matrix as a key regulator of intracellular signalling networks.

Authors:  Jordan F Hastings; Joanna N Skhinas; Dirk Fey; David R Croucher; Thomas R Cox
Journal:  Br J Pharmacol       Date:  2018-04-19       Impact factor: 8.739

4.  Characterizing the efficacy of cancer therapeutics in patient-derived xenograft models of metastatic breast cancer.

Authors:  Tia H Turner; Mohammad A Alzubi; Sahib S Sohal; Amy L Olex; Mikhail G Dozmorov; J Chuck Harrell
Journal:  Breast Cancer Res Treat       Date:  2018-03-12       Impact factor: 4.872

5.  ONECUT2 is a targetable master regulator of lethal prostate cancer that suppresses the androgen axis.

Authors:  Mirja Rotinen; Sungyong You; Julie Yang; Simon G Coetzee; Mariana Reis-Sobreiro; Wen-Chin Huang; Fangjin Huang; Xinlei Pan; Alberto Yáñez; Dennis J Hazelett; Chia-Yi Chu; Kenneth Steadman; Colm M Morrissey; Peter S Nelson; Eva Corey; Leland W K Chung; Stephen J Freedland; Dolores Di Vizio; Isla P Garraway; Ramachandran Murali; Beatrice S Knudsen; Michael R Freeman
Journal:  Nat Med       Date:  2018-11-26       Impact factor: 53.440

Review 6.  Pre-metastatic niches: organ-specific homes for metastases.

Authors:  Héctor Peinado; Haiying Zhang; Irina R Matei; Bruno Costa-Silva; Ayuko Hoshino; Goncalo Rodrigues; Bethan Psaila; Rosandra N Kaplan; Jacqueline F Bromberg; Yibin Kang; Mina J Bissell; Thomas R Cox; Amato J Giaccia; Janine T Erler; Sachie Hiratsuka; Cyrus M Ghajar; David Lyden
Journal:  Nat Rev Cancer       Date:  2017-03-17       Impact factor: 60.716

7.  Engagement of the ICOS pathway markedly enhances efficacy of CTLA-4 blockade in cancer immunotherapy.

Authors:  Xiaozhou Fan; Sergio A Quezada; Manuel A Sepulveda; Padmanee Sharma; James P Allison
Journal:  J Exp Med       Date:  2014-03-31       Impact factor: 14.307

8.  Convergent loss of PTEN leads to clinical resistance to a PI(3)Kα inhibitor.

Authors:  Dejan Juric; Pau Castel; Malachi Griffith; Obi L Griffith; Helen H Won; Haley Ellis; Saya H Ebbesen; Benjamin J Ainscough; Avinash Ramu; Gopa Iyer; Ronak H Shah; Tiffany Huynh; Mari Mino-Kenudson; Dennis Sgroi; Steven Isakoff; Ashraf Thabet; Leila Elamine; David B Solit; Scott W Lowe; Cornelia Quadt; Malte Peters; Adnan Derti; Robert Schegel; Alan Huang; Elaine R Mardis; Michael F Berger; José Baselga; Maurizio Scaltriti
Journal:  Nature       Date:  2014-11-17       Impact factor: 49.962

9.  Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal.

Authors:  Samra Turajlic; Hang Xu; Kevin Litchfield; Andrew Rowan; Tim Chambers; Jose I Lopez; David Nicol; Tim O'Brien; James Larkin; Stuart Horswell; Mark Stares; Lewis Au; Mariam Jamal-Hanjani; Ben Challacombe; Ashish Chandra; Steve Hazell; Claudia Eichler-Jonsson; Aspasia Soultati; Simon Chowdhury; Sarah Rudman; Joanna Lynch; Archana Fernando; Gordon Stamp; Emma Nye; Faiz Jabbar; Lavinia Spain; Sharanpreet Lall; Rosa Guarch; Mary Falzon; Ian Proctor; Lisa Pickering; Martin Gore; Thomas B K Watkins; Sophia Ward; Aengus Stewart; Renzo DiNatale; Maria F Becerra; Ed Reznik; James J Hsieh; Todd A Richmond; George F Mayhew; Samantha M Hill; Catherine D McNally; Carol Jones; Heidi Rosenbaum; Stacey Stanislaw; Daniel L Burgess; Nelson R Alexander; Charles Swanton
Journal:  Cell       Date:  2018-04-12       Impact factor: 41.582

10.  Metabolic enzyme PFKFB4 activates transcriptional coactivator SRC-3 to drive breast cancer.

Authors:  Subhamoy Dasgupta; Kimal Rajapakshe; Bokai Zhu; Bryan C Nikolai; Ping Yi; Nagireddy Putluri; Jong Min Choi; Sung Y Jung; Cristian Coarfa; Thomas F Westbrook; Xiang H-F Zhang; Charles E Foulds; Sophia Y Tsai; Ming-Jer Tsai; Bert W O'Malley
Journal:  Nature       Date:  2018-04-03       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.